Home > Scientific Committee > Scientific Committee Profile

Scientific Committee
Profile

Naoki Tarui

Doctor and Founder

Seedsupply Inc.

Japan

Biography

Naoki Tarui, Ph.D., is the CEO and founder of SEEDSUPPLY, established in 2017 as a spin-off from Takeda Pharmaceutical Company. With over 35 years of experience in pharmaceutical research, Dr. Tarui is a leading authority in compound-protein binding studies and small molecule drug discovery. At Takeda, he was responsible for early drug discovery, including assay development, hit identification, and validation. Notably, he identified the hit compounds for PCABs (potassium-competitive acid blockers), contributing significantly to the creation of the world's first PCAB drug.

Dr. Tarui has been instrumental in advancing Improved Affinity Selection Mass Spectrometry (ASMS), a cutting-edge technology that enables direct and efficient binding experiments with challenging membrane proteins, such as SLC transporters and GPCRs. Under his leadership, SEEDSUPPLY has built a proprietary library of 400,000 compounds and 17,000 proteins, offering specialized screening services to accelerate drug discovery pipelines. This platform facilitates the identification of novel hit compounds and drug target proteins, positioning SEEDSUPPLY as a trusted partner in pharmaceutical innovation.

Dr. Tarui’s pioneering efforts, combining technical expertise and strategic vision, have redefined protein-ligand binding studies and contributed to breakthroughs in first-in-class drug discovery. His dedication to innovation continues to push the boundaries of drug discovery and development.

 +1-404-759-9729
Subscribe To Our Newsletter
224349
TOP